转自：山东财经报道 文｜经济导报 王伟 企查查信息显示，近日，复创共赢（青岛）企业管理合伙企业（有限合伙）成立，执行事务合伙人为上海复星高科技（集团）有限公司，出资额3.4亿元 人民币，注册地位于山东青岛崂山区，经营范围为企业管理。 从股权结构来看，复创共赢（青岛）企业管理合伙企业由上海复星高科技（集团）有限公司、青岛全时智投体育产业有限公司共同出资，出资比例分别为 55.8824%、44.1176%。 | | 直公司 | 查表版 查关系 查风险 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | 在用的篇业资淘工具 原因之一次十年度受言少之中 | 复创共赢(青岛)企业管理合伙企业(有限合伙) | க 天殿一下 | 脂 应用 ▼ | 商务合作 企业级产品 | 19 SWIP | ▲ 此处有 ... ▼ | | 基本信息 85 | 法律诉讼 | 经营风险 | 经营信息 | 公司发展 | 知识产权 | | МБ 历史信息 ◎ | | 工商信息 ● | | | | | | | 心天眼查 | | 工商信息 历史工商信息0 | | | | ...

Core Viewpoint - Recently, the establishment of "Fuchuang Gongying (Qingdao) Enterprise Management Partnership (Limited Partnership)" was announced, with a registered capital of 340 million RMB, primarily focused on enterprise management [1][2]. Group 1: Company Structure and Investment - The partnership is co-funded by Shanghai Fosun High Technology (Group) Co., Ltd. and Qingdao Quanshi Zhitu Sports Industry Co., Ltd., with respective investment ratios of 55.8824% and 44.1176% [1][2]. - Shanghai Fosun High Technology (Group) Co., Ltd. is wholly owned by Fosun International Limited, which operates in various sectors including health, happiness, wealth, and intelligent manufacturing [2][3]. Group 2: Financial Performance of Fosun International - Fosun International reported a revenue of 192.142 billion RMB in 2024, with overseas revenue accounting for 49.3% [3]. - In the first half of 2025, Fosun International achieved total revenue of 87.28 billion RMB, with overseas revenue reaching 46.67 billion RMB, representing 53% of total revenue [3]. - The company has been focusing on core industries with high growth potential while divesting from non-core assets [3]. Group 3: Qingdao Quanshi Zhitu Sports Industry Co., Ltd. - Qingdao Quanshi Zhitu Sports Industry Co., Ltd. is a small enterprise established in September 2021, with a registered capital of 10 million RMB [3]. - The company is involved in various activities including food sales, health food sales, sports event organization, and fitness services [3].

12月15-17日，世界旅游经济论坛·黑龙江2025在哈尔滨举行。本届论坛以"新质生产力：世界旅游经济 新引擎"为主题，吸引来自全球的百余位政府官员、行业领袖及知名企业家参会，共同探讨全球冰雪经 济与产业创新及文旅产业高质量发展路径。 复星国际联席CEO、复星旅文董事长徐晓亮应邀出席本次大会并发表主旨演讲。他结合全球冰雪产业发 展趋势与复星旅文的实践经验，系统阐释了冰雪产业从"雪道经济"向"度假经济"升级的内在逻辑，并分 享了推动中国冰雪产业实现高质量发展的思考与路径。 全球冰雪：不止于滑雪，更有快乐度假体验 徐晓亮指出，提到冰雪，人们往往想到的是雪道上的"速度与激情"，然而放眼全球，冰雪产业早已突 破"单一运动"的边界，迈向以体验为核心的"度假时代"。 复星旅文旗下Club Med地中海俱乐部目前在全球运营24家室外冰雪度假村，分布于阿尔卑斯山脉、北 海道、魁北克等世界级滑雪目的地。2025年雪季，Club Med冰雪度假村业务营业额超人民币50亿元， 接待游客24万人次，平均入住率约 80%，平均每日房价达6,200元。 徐晓亮认为，这一成绩的取得源于Club Med传承75年的冰雪度假精髓，核心体现在三 ...

近日，复星国际发布公告称，复星医药产业与绿谷科技及相关方签订交易协议，拟收购市隐投资及识璧 润合计持有的绿谷科技8.6667%股权，代价为人民币1.43亿元；同时以人民币12.69亿元认购绿谷科技新 增注册资本，占交易完成后46.3504%股权。此外，复星医药产业与绿谷科技创始人共同设立SPV，分别 持股51%和49%，SPV将以1元受让上海耀期九持有的相当于交易完成后2%的绿谷科技股份。交易完成 后，复星国际通过复星医药间接持有绿谷科技53%股权，绿谷科技成为附属公司；若创始人行使选择 权，持股比例将调整至51%。本次交易构成须予披露交易，符合上市规则第14章规定。目标公司主要从 事神经退行性疾病治疗药物研发，其甘露特钠胶囊用于轻中度阿尔茨海默病治疗。 截至2025年12月16日收盘，复星国际（00656）报收于4.63元，较前一交易日下跌3.14%，该股当日开盘 4.76元，最高4.76元，最低4.58元，成交额达2073.76万元。近52周最高6.81元，最低3.72元。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 最新公 ...

Core Viewpoint - Fosun International (00656.HK) announced an agreement to acquire a stake in Green Valley (Shanghai) Pharmaceutical Technology, enhancing its position in the Alzheimer's disease treatment market [1][2]. Group 1: Acquisition Details - Fosun Pharma's subsidiary will acquire a total of 8.6667% equity in Green Valley, with a purchase price of RMB 143 million, and will subscribe to an additional capital increase of RMB 1,269,481,633, resulting in a total ownership of 46.3504% post-transaction [1]. - The transaction involves a special purpose vehicle (SPV) where Fosun Pharma and the founders will hold 51% and 49% stakes, respectively, facilitating the handling of employee stock buybacks [2]. Group 2: Market Context - Alzheimer's disease (AD) is a significant public health challenge with limited treatment options, and the market for AD treatments in China is underdeveloped, presenting substantial growth opportunities [3]. - The global sales for AD treatments are projected to reach approximately USD 2.094 billion in 2024, while the sales in China are expected to be only RMB 1.244 billion [3]. Group 3: Product Pipeline - The target company's Mannoheptulose capsules are indicated for mild to moderate Alzheimer's disease, showing significant cognitive improvement in clinical trials [4]. - Fosun Pharma is committed to advancing its product pipeline in the central nervous system disease sector, including ongoing clinical trials and the introduction of innovative treatment technologies [4].

Core Viewpoint - Fosun International announced an agreement to acquire a stake in Green Valley (Shanghai) Pharmaceutical Technology, enhancing its position in the Alzheimer's disease treatment market [1][2][3] Group 1: Acquisition Details - Fosun Pharma will acquire a total of 8.6667% of Green Valley's shares, with a purchase price of RMB 143 million, and will subscribe to additional registered capital amounting to RMB 1.269 billion, resulting in a total ownership of 46.3504% post-transaction [1][2] - The transaction involves a special purpose vehicle (SPV) where Fosun Pharma and the founders of Green Valley will hold 51% and 49% stakes, respectively, to manage employee buyback arrangements [2] Group 2: Market Context - Alzheimer's disease (AD) is a significant public health challenge with limited treatment options, and the market for AD treatments in China shows substantial growth potential, with a current sales figure of RMB 1.244 billion for 2024 [3][4] - The market for AD treatments globally is projected to reach USD 2.094 billion in 2024, indicating a strong demand for effective therapies [3] Group 3: Product Pipeline - Green Valley's Mannoheptulose capsules are aimed at treating mild to moderate Alzheimer's disease, showing significant cognitive improvement in clinical trials [4] - Fosun Pharma is expanding its product pipeline in the central nervous system disease sector, including non-invasive diagnostic and therapeutic solutions, and plans to conduct further clinical trials for the newly acquired drug [4]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該 等內容而引致的任何損失承擔任何責任。 須予披露交易 有關控股綠谷科技 交易 於 2025 年 12 月 15 日，復星醫藥產業（本公司透過復星醫藥持有之附屬公司） 與目標公司、目標公司創始股東、若干目標公司現有股東及若干目標公司之附 屬公司簽訂交易協議，據此，復星醫藥產業同意收購，市隱投資及識璧潤同意 出售其分別持有的目標公司 6.8817%及 1.7849%的股權，合計佔交易前目標公 司 8.6667%的股權（佔交易完成後目標公司 4.6496%的股權），收購事項之代價 合計為人民幣 143,000,000 元；各方同意復星醫藥產業以人民幣 1,269,481,633 元認購目標公司新增註冊資本（佔交易完成後目標公司 46.3504%的股權）。 此外，為妥善處理目標公司存續股權激勵計劃等安排中的相關退股並由復星醫 藥產業和目標公司創始人共同承擔相應成本，擬由目標公司先行向約定範圍內 的退股員工等支付相應退股款項，同時由復星醫藥產業與目標公 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年11月30日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 復星國際有限公司 | | | 呈交日期: | 2025年12月3日 | | | I. 法定/註冊股本變動 | 不適用 | | FF301 第 1 頁 共 10 頁 v 1.1.1 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00656 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 8,166,635,624 | | 0 | | 8,166,635,624 | | 增加 / 減少 (-) | | | 0 | ...

Summary of FOSUN International Conference Call Company Overview - **Company**: FOSUN International - **Industry**: Diversified Investments, Pharmaceuticals, Insurance, Consumer Goods Key Points Strategic Transformation - FOSUN International is undergoing a strategic transformation focusing on core businesses and exiting non-core assets, aiming to increase overseas revenue contribution to 60% and significantly reduce debt levels, targeting interest-bearing liabilities below 60 billion RMB and public market debt to 25% [2][6][3] Business Segments - **Domestic Business**: - Focus on consumer sectors, including gold jewelry and cultural tourism through Yuyuan [4] - Innovation in pharmaceuticals represented by FOSUN Pharma [4][5] - **Overseas Business**: - Key investments in Portuguese insurance and consumer brands like Club Med, contributing to nearly 30% of total overseas revenue [4][10] Financial Goals - Plans to reduce interest-bearing debt from a peak of 120 billion RMB to 89 billion RMB, with a further target of 60 billion RMB [6] - Aiming to restore group operating profit and net profit attributable to shareholders to 10 billion RMB, while gradually increasing the dividend payout ratio from 20% to 50% over the next 3-5 years [6][13] Innovation in Pharmaceuticals - FOSUN Pharma is accelerating its transition to innovative drugs, with expectations for rapid growth post-2027, supported by a global R&D center and innovative drug platform [2][9] - Currently, there are multiple innovative drugs in the pipeline with global sales potential between 5 billion to 10 billion USD [9] Geographic Risk Management - The company employs a strategy combining globalization with local operations to mitigate geopolitical risks, particularly in Europe and North America [7][11] - In Europe, the Portuguese insurance business is expected to maintain a premium income growth rate of 10%-15% over the next five years, with significant profit growth potential due to low current ROE [10] Asset Disposal Strategy - FOSUN International has identified approximately 90 billion to 100 billion RMB worth of assets for disposal, including real estate and non-core investments, aiming to generate cash flow to reduce debt [12] - Specific assets include real estate valued at around 30 billion RMB and non-core secondary market holdings [12] Dividend Policy - The company plans to gradually increase its dividend payout ratio to enhance shareholder returns, with a target of achieving 10 billion RMB in operating profit [13] Competitive Position in Pharmaceuticals - FOSUN Pharma is transitioning from generics to innovative drugs, with significant investments in R&D and a focus on global commercialization capabilities [14][15] - The company is committed to maintaining a competitive edge through substantial annual investments in innovation and development [15] Real Estate Disposal Insights - The company evaluates real estate project sales based on market conditions and potential for appreciation, indicating a flexible pricing strategy [16]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產 生或因倚賴該等內容而引致的任何損失承擔任何責任。 持續關連交易 有關訂立互供框架協議 互供框架協議 於 2025 年 11 月 28 日，復星醫藥（本公司之附屬公司 ）與重藥控股訂立互供 框架協議，內容有關 復星醫藥集團 向重藥控股集團供應銷售產品及購買採購 產品，以及 復星醫藥集團 與重藥控股集團互相提供服務，自 2026 年 1 月 1 日起至 2028 年 12 月 31 日止，為期 3 年。 香 港 上市規則之涵義 重藥控股 為 重慶藥友（本公司 及復星醫藥之間接非全資附屬公司）之主要股 東，因此，根據香港上市規則第 14A.07(1)條，重藥控股為本公司於附屬公司 層面之關連人士，故根據香港上市規則第 14A 章，互供框架協議項下擬進行 之交易構成本公司之持續關連交易。但因 (1)重藥控股為本公司於附屬公司層 面之關連人士；(2)董事會已批准互供框架協議及其項下擬進行之交易，及 (3) 獨立 非 執行 董 事已 確認，互 供框 架 協議 乃按 ...